As the current COO of Linnaeus Therapeutics, she is driving the development of their lead therapeutic through Phase 2 clinical trials for both oncology and healthspan extension, with support from the ARPA-H PROSPR and NIA-ITP programs. Prior to Linnaeus, she partnered Chromocell’s lead anti-pain asset with Astellas and brought it into the clinic. She has also founded MaxSAR Therapeutics which did high-throughput, metabolism inspired, SAR, led global assay development and screening at Sanofi, developed and partnered a novel 1536 well-less plate system with Becton Dickinson while at Merck, and designed the first commercial instrument for fine structure analysis of DNA and deployed it into the Mayo Clinic. Tina is a current board member of Epistemi and BBBCA and an angel investor with MidAtlantic BioAngels. Previously she has been a board member or advisor at St. Jude’s, SLAS, NCI, Corning, several start-ups, etc.
